目的 調(diào)查分析多西他賽致過敏性休克的發(fā)生特點(diǎn)與防治規(guī)律，為臨床安全用藥提供參考。方法 檢索PubMed、Medline、中國學(xué)術(shù)期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫（CBM）、萬方數(shù)據(jù)庫和維普中文期刊全文數(shù)據(jù)庫（VIP）中有關(guān)多西他賽致過敏性休克的個案病例，時間為1996年1月—2019年1月；對發(fā)生人群分布、合并用藥情況及患者臨床癥狀等進(jìn)行統(tǒng)計學(xué)分析。結(jié)果 獲21篇個案病例，共25例患者，其中男7例、女18例，年齡在50～59歲發(fā)生過敏性休克占比最高（48.00%），其中男、4例、女、8例，誘導(dǎo)期主要集中于0～5 min內(nèi)（占56%）。合并用藥、多西他賽給藥量（溶媒）及滴速與患者發(fā)生過敏性休克未見線性關(guān)系。藥物與不良事件因果關(guān)系諾氏（Naranjo’s）評分：肯定有關(guān)7例（28.00%），很可能有關(guān)16例（64.00%）。結(jié)論 多西他賽致過敏性休克宜發(fā)于化療初期，多見于中老年患者，臨床用藥時宜對該類人群重點(diǎn)監(jiān)護(hù)，且輔以長時隨訪，以免藥源性損害。

Objective To analyze the characteristics and general patterns of anaphylactic shock by docetaxel and provide a reference for clinical use. Methods Search of Pubmed, Medline, CNKI, CBM, WanFang Data, andVIP databases of anaphylactic shock induced by docetaxel, from January 1996 to January 2019. Statistical analysis of population distribution, combined use of drugs and clinical symptoms of the patients was carried out. Results There were 21 cases reported in a total of 25 patients, among them 7 males and 18 females. The incidence of anaphylactic shock was the highest (48.00%) between 50 and 59 years of age, of which 4 were male and 8 were female. The induction period was mainly concentrated in 0-5 min, accounting for 56%. And there was no linear relationship between the combined medication, docetaxel dosage (solvent), drop rate and anaphylactic shock. Naranjo's score of causal relationship between drugs and adverse events:positive in 7 cases (28.00%), most likely in 16 cases (64.00%). Conclusion The anaphylactic shock induced by docetaxel should occur in the early stage of chemotherapy, which is usually seen in middle-aged and elderly patients. The clinical use of docetaxel should be monitored in a timely manner, supplemented by long-term follow-up, so as to avoid drug-induced damage